BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2687409)

  • 1. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
    Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The usefulness and limitation of sugar antigen in ovarian cancers--with special reference to a new tumor marker, CA54/61].
    Nozawa S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1147-51. PubMed ID: 2499263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated mucin-type glycoprotein (CA54/61) defined by two monoclonal antibodies (MA54 and MA61) in ovarian cancers.
    Nozawa S; Yajima M; Kojima K; Iizuka R; Mochizuki H; Sugawara T; Iwamori M; Nagai Y
    Cancer Res; 1989 Jan; 49(2):493-8. PubMed ID: 2910468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
    Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
    Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
    Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
    Shi ZL
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
    Yakushiji M; Nishimura H
    Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
    Kobayashi H; Ohi H; Shinohara H; Terao T
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On the clinical usefulness of a few sugar antigens and a galactosyl-transferase].
    Nozawa S; Izumi S; Sakayori M; Narisawa S; Kojima K; Iizuka R; Iwamori M; Nagai Y
    Hum Cell; 1988 Mar; 1(1):37-45. PubMed ID: 3155288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.